Articles On Immutep (ASX:IMM)

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

ShareCafeIron ore surge not enough to lift the ASX: Aus shares close 0.16% lower by Peter Milios   Iron ore prices have reached a seven-month high due to increased demand expectations from China after its reopening following a Covid-19 surg...

ShareCafeASX down 0.15% at noon despite spike in US markets by Peter Milios   The global race for lithium, a commodity crucial for the electric vehicle (EV) industry, has intensified as German Chancellor Olaf Scholz signed an agreement with...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

The ASX will open higher this morning, defying a slump in New York Tesla shares plunged 12% Oil prices tumbled on recession fears   Aussie shares are set to open higher this morning despite a fall in New York. At 8am AEDT, the ASX 200 Jan...

Immutep (IMM) completes 50 per cent of patient enrolment for its TACTI-003 phase IIb trial The trial is designed to evaluate Immutep’s first-in-class soluble LAG-3 protein, efti, in combination with KEYTRUDA as first line treatment of re...

Little joy for investors in December with traditional Christmas rally not eventuating in 2022 Meteoric Resources leads December winners after positive metallurgical results at its new Caldeira project. Symbio Holdings saw its share price p...

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

Weekly broker wrap: insurers more resilient, healthcare picks, contractors remain labour-reliant, classifieds look resilient, retail braces for decline. -Climate resilience supports domestic insurance outlook-Wilsons lists healthcare sector...

ShareCafeLithium slammed by GS, NSW close to energy deal with Federal Government: ASX closes 0.6% lower by Peter Milios   Goldman Sachs have extended their bearish views on lithium, believing that the prices are expected to decline from the...

ShareCafeLithium stocks under pressure following Goldman’s comments: ASX down 0.47% at noon by Lauren Hayes   The Australian market is still unnerved over concerns about a possible US recession. Energy is weighing down the benchmark over fe...

Immutep (IMM) achieves commercial scale manufacturing of its lead product candidate, eftilagimod alpha (efti)The company completed its first 2000-litre manufacturing run of efti, a first-in-class soluble LAG-3 proteinImmutep has been workin...

Imagion presents positive data at world leading symposium Osteopore expands in Southeast Asia Microba expands into Italy and Portugal   Imagion speaks at world-leading breast cancer symposium Imagion Biosystems (ASX:IBX) is set to rise ov...

ShareCafeShares dip following rate hike: ASX closes 0.5% lower by Peter Milios   The ASX has closed 0.47 per cent lower after the Reserve Bank of Australia delivered its eighth interest rate hike in a row, lifting the cash rate 25 basis hig...

ShareCafeLocal market awaits RBA rate decision: ASX falls 0.17% at noon by Lauren Hayes   The Australian market has followed Wall Street’s negative lead overnight after US markets sold off on fears that the Fed will keep increasing interest...

Well, it’s rates day here in Oz, and property owners are donning their brownest pants for a likely rise. Some say 50bps is sensible. In the US, the Fed got a case to keep rising rates despite the inflationary slowdown. Stronger than expecte...

ShareCafeThe Week that Was: November 28-December 2, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier...

ASX Health sector is continuing its upward trend, marginally up this week 0.87%  Sonic Healthcare announces a plan to acquire ~20% holding of Microba Life Sciences Mayne Pharma shares takes a hit after company warns it won’t hit positive e...

ShareCafeIron ore climbs to highest price since September: ASX closes 0.3% higher by Peter Milios   Singaporean iron ore futures have soared above the US$100 per tonne for the first time since September, resulting in gains for ASX-listed ir...

Immutep (IMM) signs another collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a phase one clinical studyThe companies will conduct and jointly fund the INSIGHT-005 trial in Germany to evaluate Immutep’s efti product...

ShareCafeChinese protests over lockdowns continue: Aus shares 0.07% lower at noon by Peter Milios   The global economic outlook is shaky, as growing protests in the world’s largest manufacturing nation are creating a new level of uncertaint...

Sonic has taken a stake in Microba Immutep enters into second deal with Merck (Germany) and Pfizer  ImpediMed has a new CEO   Sonic takes strategic stake in Microba Giant healthcare stock Sonic Healthcare (ASX:SHL) has bought a stake in s...

Immutep (ASX:IMM) has announced a new clinical trial collaboration under which the Australian company's investigative LAG-3 immunotherapy, efti, will be studied with Merck and Pfizer's PBS-listed BAVENCIO (avelumab).

The ASX is set to open slightly higher on Tuesday Wall Street fell almost 2% overnight as protests in China spread Crypto lender BlockFi has filed for bankruptcy The ASX is poised to edge slightly higher on Tuesday despite a 1.5% – 1.75%...

ShareCafeImmutep (ASX: IMM) – A Transformative Year for LAG-3 Therapies Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company’s portfolio of therapies, encouraging data from the 2022 SIT...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

ShareCafeEarly gains quickly wiped off: ASX closes the day 0.16% lower by Peter Milios   All sectors except Materials and Energy are lower in today’s day of trading, as the ASX finishes 0.16 per cent or 11.70 points lower at 7146.30. Materi...

The ASX gave up early gains as last week’s fierce global share rally showed signs of losing momentum.   The S&P/ASX 200 touched a five-month high before fading to a loss of 12 points or 0.16 per cent. The decline came as Asian mar...

ShareCafeMarket losing momentum, materials the saviour: ASX flat at noon by Lauren Hayes   Last week’s gains have not continued with the same momentum this morning. Materials, up 3.4 per cent, is bolstering the local market following a rise...

The share market touched a five-month high before shedding its gains as a decline in US futures undermined a China-fuelled rally in resource stocks. The S&P/ASX 200 rallied to within four points of 7200 for the first time since June....

Immutep (IMM) receives a $986,000 tax refund from the Australian government’s research and development (R&D) tax incentive programThe cash rebate is mostly for money Immutep spent on its clinical study work during its 2021 financial yea...

Highlights Australian shares opened higher on Monday. The ASX 200 gained in the opening trade, rising 25.20 points, or 0.35%, to 7,183.20. On Friday, the benchmark index closed 2.8% higher at 7,158 points. Australian s...

Imugene (IMU) presents new data for its onCARlytics oncolytic virus at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, USThe company presented two different sets — the first for a treatment with fellow biotec...

Immutep (IMM) receives two new patents from the Japanese Patent Office and South Korean Patent Office for its immunotherapy treatment for cancerThe new patent protects Immutep’s intellectual property relating to combined therapeutic prepara...

ShareCafeA sea of red in today’s trading: ASX closes 1.84% lower by Peter Milios   All but one sector finished lower today, as the ASX reacted to the overnight news that the Fed has increased rates by 75 basis points. Materials, Consumer Di...

ShareCafeAll red across the board following US rate hike sentiment: ASX down 1.96% at noon By Lauren Hayes   US equities plunged after Fed Chair Jerome Powell indicated policymakers would continue raising interest rates to fight persistent...

The All Ordinaries Index (ASX: XAO) may be sinking today but that hasn’t stopped a couple of ASX healthcare shares from racing higher. Here’s why these two All Ords shares are smashing the index on Thursday: Immutep Ltd (ASX: IMM) The...

HitIQ signs deal with Western Australian Football Commission Rhthym Bio expands into NZ Immutep’s Phase II TACTI-002 trial has been accepted for an oral presentation HitIQ signs with WAFC Concussion tech specialist HitIQ (ASX:HIQ) rose 40...

The ASX is set to plunge on Thursday after a crash in New York US Fed unleashed another jumbo 75bp rate hike Fed boss Jerome Powell spooked the markets during his speech   The ASX is poised to plunge on Wednesday, tracking movements in Ne...

ShareCafeASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon by Peter Milios   Last week’s rally for US equities ground to a halt overnight ahead of this week’s Federal Reserve decision on interest rates, as te...

Immutep (IMM) is given approval by the Independent Data Monitoring Committee (IDMC) to carry on with its planned phase IIb TACTI-003 trialThe IDMC reviewed the initial safety data and concluded that the trial should continue with no modific...

ShareCafeMarket unfazed by CPI data: ASX finishes 0.18% higher by Peter Milios   CPI data from the September quarter has sharply exceeded estimates. As such, multiple banks have made predictions for the next rate rise. Commonwealth Bank (AS...

ShareCafeAustralian headline inflation hits highest in 32 years: ASX up 0.12% at noon by Lauren Hayes   The S&P/ASX 200 posted gains this morning as sentiment from Wall Street overnight improved over the Fed potentially turning less agg...

Neurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closing Perth R&D facility to focus on invariant Natural Killer T (iNKT) cell platform Argenica reports safety and efficiacy of stroke drug A...

ShareCafeEnergy and Materials only sectors left lagging: ASX closes 0.28% higher by Peter Milios   In today’s events, independent commission agency ASIC has launched legal action against BPS Financial, the company behind Gold Coast-based di...

ShareCafeOptimism out of the US boosts sentiment: ASX up 0.6% at noon by Lauren Hayes   Positive gains in the local market have extended into a second day as optimism out of the US about corporate earnings ahead of several key tech reports...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

ShareCafeImmutep (ASX: IMM) Receives Fast Track Designation from FDA   Immutep Limited (ASX: IMM) CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company...

Emerging gold miner Tietto Minerals has a new Chinese Mining giant as a substantial shareholder Environment play LGI has new substantial shareholders since listing on the ASX last week Lunnon Metals loses substantial shareholders while Bas...

During latest period of volatility many health stocks have seen their share prices remain quite stable Several ASX health stocks have rallied this week on positive news including Polynovo on $5 million sales month Telix Pharmaceuticals ral...